Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 5/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164384 | 0.86 | MEN1 (0.56) | MEN1KMT2ACCR5SLC6A2SLC6A4 | |
| SCHEMBL4027887 | 0.86 | L3MBTL1 (0.57) | MEN1KMT2ACCR5SLC6A2SLC6A4 | |
| SCHEMBL340742 | 0.85 | TACR1 (0.52) | MBTPS1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL6397313 | 0.84 | SLC6A2 (0.52) | MBTPS1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4158712 | 0.84 | MEN1 (0.54) | MEN1KMT2AMBTPS1CCR5SLC6A2 | |
| SCHEMBL2769377 | 0.83 | KCNH2 (0.61) | MEN1KMT2ACCR5KCNH2GPR119 | |
| SCHEMBL27712416 | 0.82 | TACR1 (0.49) | MBTPS1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4158615 | 0.82 | CCR5 (0.59) | MEN1KMT2ACCR5SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4025121 | 0.82 | KCNH2 (0.60) | MEN1KMT2ACCR5KCNH2GPR119 | |
| SCHEMBL341681 | 0.82 | TACR1 (0.49) | MBTPS1SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| CN-1856305-B | Pyridine derivatives as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD | 2010-04-28 | — | — | CN | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | MEN1 1845/4885KMT2A 3265/4885MBTPS1 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.